Bridge-to-transplant temporary mechanical circulatory support and risk of allosensitization.
allosensitization
heart transplant
temporary mechanical circulatory support
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
revised:
07
04
2024
received:
13
12
2023
accepted:
22
04
2024
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
8
5
2024
Statut:
ppublish
Résumé
Since the 2018 change in the US adult heart allocation policy, more patients are bridged-to-transplant on temporary mechanical circulatory support (tMCS). Previous studies indicate that durable left ventricular assist devices (LVAD) may lead to allosensitization. The goal of this study was to assess whether tMCS implantation is associated with changes in sensitization. We included patients evaluated for heart transplants between 2015 and 2022 who had alloantibody measured before and after MCS implantation. Allosensitization was defined as development of new alloantibodies after tMCS implant. A total of 41 patients received tMCS before transplant. Nine (22.0%) patients developed alloantibodies following tMCS implantation: 3 (12.0%) in the intra-aortic balloon pump group (n = 25), 2 (28.6%) in the microaxial percutaneous LVAD group (n = 7), and 4 (44.4%) in the veno-arterial extra-corporeal membrane oxygenation group (n = 9)-p = .039. Sensitized patients were younger (44.7 ± 11.6 years vs. 54.3 ± 12.5 years, p = .044), were more likely to be sensitized at baseline - 3 of 9 (33.3%) compared to 2 out of 32 (6.3%) (p = .028) and received more transfusions with red blood cells (6 (66.6%) vs. 8 (25%), p = .02) and platelets (6 (66.6%) vs. 5 (15.6%), p = .002). There was no significant difference in tMCS median duration of support (4 [3,15] days vs. 8.5 [5,14.5] days, p = .57). Importantly, out of the 11 patients who received a durable LVAD after tMCS, 5 (45.5%) became sensitized, compared to 4 out of 30 patients (13.3%) who only had tMCS-p = .028. Our findings suggest that patients bridged-to-transplant with tMCS, without significant blood product transfusions and a subsequent durable LVAD implant, have a low risk of allosensitization. Further studies are needed to confirm our findings and determine whether risk of sensitization varies by type of tMCS and duration of support.
Substances chimiques
Isoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15330Subventions
Organisme : NHLBI NIH HHS
Pays : United States
Informations de copyright
© 2024 The Authors. Clinical Transplantation published by John Wiley & Sons Ltd.
Références
John R, Lietz K, Schuster M, et al. Immunologic sensitization in recipients of left ventricular assist devices. J Thorac Cardiovasc Surg. 2003;125(3):578‐591.
McKenna DH Jr, Eastlund T, Segall M, Noreen HJ, Park S. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant. 2002;21(11):1218‐1224.
Drakos SG, Kfoury AG, Kotter JR, et al. Prior human leukocyte antigen‐allosensitization and left ventricular assist device type affect degree of post‐implantation human leukocyte antigen‐allosensitization. J Heart Lung Transplant. 2009;28(8):838‐842.
Tsau PH, Arabia FA, Toporoff B, Paramesh V, Sethi GK, Copeland JG. Positive panel reactive antibody titers in patients bridged to transplantation with a mechanical assist device: risk factors and treatment. ASAIO J. 1998;44(5):M634‐637.
De Mattos AM, Head MA, Everett J, et al. HLA‐DR mismatching correlates with early cardiac allograft rejection, incidence, and graft survival when high‐confidence‐level serological DR typing is used. Transplantation. 1994;57(4):626‐630.
Joyce DL, Southard RE, Torre‐Amione G, Noon GP, Land GA, Loebe M. Impact of left ventricular assist device (LVAD)‐mediated humoral sensitization on post‐transplant outcomes. J Heart Lung Transplant. 2005;24(12):2054‐2059.
Zerbe TR, Arena VC, Kormos RL, Griffith BP, Hardesty RL, Duquesnoy RJ. Histocompatibility and other risk factors for histological rejection of human cardiac allografts during the first three months following transplantation. Transplantation. 1991;52(3):485‐490.
Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg. 2001;122(6):1186‐1195.
Cole R, Moriguchi J, Kittleson M, et al. Do temporary mechanical circulatory support devices activate sensitization pathways in patients awaiting heart transplantation? J Heart Lung Transplant. 2022;41(4):S469. Supplement.
Goetz RL, Kaleekal TS, Wille KM, et al. HLA sensitization in patients bridged to lung transplantation with extracorporeal membrane oxygenation. Transplant Direct. 2023;9(7):e1497.
Alam A, van Zyl JS, McKean S, et al. Does temporary mechanical circulatory support with Impella 5.5 induce de novo human leukocyte antigen antibodies production in heart transplantation candidates? JHLT Open. 2024;4:100072.